Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Albumin Nanocarriers for Enhanced Curcumin Delivery and In Vitro Anticancer Activity in Colon Cancer Cells.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Comparative Efficacy of Four Different Types of Medicaments for Pulpotomy of Primary Molars: A Clinical and Radiographic Study.

International journal of clinical pediatric dentistry·2026
Same author

Macrophage in the crosshairs: chemical inhalation and lung immune defense.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Kaempferol-loaded solid lipid nanoparticles attenuate cartilage degradation and inflammation by modulating the expression of pro and inflammatory cytokines, MMP-13 and oxidative stress markers in adjuvant induced arthritic rats.

Inflammopharmacology·2026
Same author

Rosemary leaves extract mediated green synthesis of silver functionalized BiFeO<sub>3</sub> nanoparticles with improved visible light photocatalytic performance.

Discover nano·2026
Same author

CRISPR/Cas9-mediated editing of the <i>GhJAZ2</i> gene improves fiber length and lint percentage in <i>Gossypium hirsutum</i> L.

GM crops & food·2026

Related Experiment Video

Updated: Jun 4, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Cardiorenal syndromes.

Peter A McCullough1, Aftab Ahmad

  • 1Peter A McCullough, Aftab Ahmad, Department of Medicine, Cardiology Section, St. John Providence Health System, Providence Park Hospital, Novi, MI 48374, United States.

World Journal of Cardiology
|February 3, 2011
PubMed
Summary
This summary is machine-generated.

Cardiorenal syndromes (CRS) involve bidirectional heart and kidney injury. This review explores five CRS types, their mechanisms, and the role of biomarkers in understanding these conditions.

Keywords:
Biological biomarkersCardiovascular diseasesCreatinineHeart diseasesKidney diseases

More Related Videos

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

Related Experiment Videos

Last Updated: Jun 4, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

Area of Science:

  • Cardiology
  • Nephrology
  • Biomarkers

Background:

  • Cardiorenal syndromes (CRS) are characterized by bidirectional injury between the heart and kidneys.
  • Five distinct types of CRS have been defined, each involving specific pathways of cardiac and renal dysfunction.
  • Oxidative stress and apoptosis are identified as common pathways in CRS pathogenesis.

Purpose of the Study:

  • To review the classification and pathophysiology of the five defined types of cardiorenal syndromes.
  • To explore the role of blood and urine biomarkers in understanding CRS.
  • To enhance the comprehension of CRS epidemiology and underlying mechanisms.

Main Methods:

  • Review of existing literature on cardiorenal syndromes.
  • Analysis of the subclassification of CRS into five types.
  • Examination of cellular mechanisms including cell-to-cell death and apoptosis.
  • Discussion of biomarker utility in CRS.

Main Results:

  • Cardiorenal syndromes are classified into five types based on the interplay between cardiac and renal dysfunction.
  • Types 1 and 2 involve cardiovascular disease impacting the kidneys, while Types 3 and 4 involve kidney disease impacting the heart.
  • Type 5 CRS represents simultaneous injury to both organs, as seen in sepsis.
  • Biomarkers in blood and urine are crucial for understanding CRS pathophysiology and epidemiology.

Conclusions:

  • The five types of cardiorenal syndromes provide a framework for understanding complex heart-kidney interactions.
  • Oxidative stress and apoptosis are key mediators in the development of CRS.
  • Biomarkers hold significant potential for improving the diagnosis, prognosis, and management of cardiorenal syndromes.